Patient Safety & Systems-Based Practice

Adverse drug events: identification and prevention

Clinical Overview and When to Suspect an Adverse Drug Event

— ADEs cause ~1.3 million ED visits and ~350,000 hospitalizations annually in the US

— Account for ~5% of hospital admissions in adults; up to 20% in the elderly

— Roughly half are considered preventable through systems-level fixes

— New symptom developing within days to weeks of starting, stopping, or dose-changing a medication

— Unexplained electrolyte derangement, AKI, LFT bump, cytopenia, QT prolongation, mental status change, fall, or rash in a patient on polypharmacy

— Symptom that "fits" a known class effect (e.g., dry cough on ACEi, myalgias on statin, confusion on anticholinergic)

— Symptoms improve with dechallenge or recur with rechallenge (Naranjo scale criteria)

— Age ≥65, CKD, hepatic impairment, ≥5 medications (polypharmacy)

— Recent care transition (hospital→home, SNF→home) — peak ADE window is 0–30 days post-discharge

— Low health literacy, multiple prescribers, lack of medication reconciliation

Definition: An adverse drug event (ADE) is any injury resulting from medical intervention related to a drug — includes adverse drug reactions (ADRs), medication errors causing harm, overdoses, and non-adherence harms.

Scale of the problem:

When to suspect ADE in any patient encounter:

High-risk drug classes (the "ADE big 7"): anticoagulants, insulin/oral hypoglycemics, opioids, antibiotics, antiplatelets, digoxin, and chemotherapy — these drive most ED visits and inpatient harms.

High-risk patient features:

Step 3 management: On every ambulatory and discharge encounter, perform medication reconciliation — list all prescription, OTC, herbal, and PRN agents; ask about adherence; flag duplications and interactions before adding a new drug.

Board pearl: A "new symptom in a patient on chronic meds" stem is an ADE until proven otherwise — resist the urge to add a drug to treat a drug side effect (the prescribing cascade).

Presentation Patterns and Key History

— Temporal pattern: symptom onset clearly tied to a new drug or dose escalation (e.g., angioedema 2 days after lisinopril start)

— Class effect: symptom matches a textbook side effect profile (dry cough/ACEi, peripheral edema/amlodipine, hyperkalemia/spironolactone)

— Drug–drug interaction: symptom appears when a second drug is added (e.g., rhabdomyolysis when clarithromycin added to simvastatin)

— Cumulative toxicity: symptom emerges weeks–months after stable dosing as the drug accumulates (digoxin in worsening CKD, lithium in dehydration)

— Withdrawal syndrome: symptom appears on dose reduction or discontinuation (benzodiazepine withdrawal, SSRI discontinuation, beta-blocker rebound)

— Exact drug name, dose, frequency, start date, and last dose

— All OTC agents (NSAIDs, PPIs, antihistamines), supplements (St. John's wort, ginkgo), and recreational drugs

— Recent antibiotic course (warfarin INR derangement, C. difficile, QT)

— Adherence: missed doses, doubled doses, pill-splitting, expired prescriptions

— Recent dose changes by any prescriber (PCP, specialist, urgent care)

— Prior reactions to drugs and family history of drug allergies

— "Show me all your pill bottles" (brown-bag review)

— Any new dizziness, falls, confusion, urinary retention, constipation since the last visit?

— Have you been to the ED or hospital since I last saw you? (transition window!)

Five archetypal ADE presentations on Step 3:

Targeted history elements:

Useful screening questions for the elderly:

Key distinction: A true drug allergy is immune-mediated (IgE urticaria/anaphylaxis, T-cell SJS/DRESS) and contraindicates rechallenge; a drug intolerance (statin myalgia, metformin GI upset) is dose-related and often allows continued use at lower dose or with adjuncts.

Board pearl: Always ask about grapefruit juice (CYP3A4 inhibition — simvastatin, calcium channel blockers, immunosuppressants) and OTC NSAIDs (HTN exacerbation, AKI, GI bleed in elderly on anticoagulants).

Physical Exam Findings and Bedside Assessment

— Hypotension: antihypertensives, diuretics, alpha-blockers (first-dose syncope), opioids, vasodilators

— Hypertension: NSAIDs, decongestants, stimulants, MAOI + tyramine, withdrawal (clonidine, beta-blockers)

— Bradycardia: beta-blockers, non-DHP CCBs, digoxin, donepezil, clonidine

— Tachycardia: anticholinergics, beta-agonists, withdrawal syndromes, thyroid hormone

— Hyperthermia: serotonin syndrome, neuroleptic malignant syndrome, anticholinergic toxidrome, malignant hyperthermia

— Serotonergic: clonus (especially lower extremity), hyperreflexia, agitation, mydriasis, diaphoresis — onset hours

— Anticholinergic: "hot, dry, red, blind, mad" — flushed dry skin, urinary retention, mydriasis, delirium

— Cholinergic: SLUDGE — salivation, lacrimation, urination, defecation, GI cramping, emesis; miosis

— NMS: lead-pipe rigidity, hyperthermia, autonomic instability, altered mentation — onset days–weeks; dopamine antagonists

— Opioid: miosis, respiratory depression, decreased mentation

— Mucosal involvement, skin tenderness, blistering, Nikolsky sign → SJS/TEN

— Facial edema, lymphadenopathy, eosinophilia, fever → DRESS (usually 2–8 weeks post-start; aromatic anticonvulsants, allopurinol, sulfonamides)

— Targetoid lesions, palms/soles involvement → erythema multiforme

— Gingival hyperplasia: phenytoin, cyclosporine, nifedipine

— Gynecomastia: spironolactone, cimetidine, ketoconazole, finasteride

— Parkinsonism/akathisia/tardive dyskinesia: metoclopramide, antipsychotics

Vitals as ADE clues:

Targeted exam by toxidrome:

Dermatologic red flags requiring immediate drug discontinuation:

Other focused findings:

CCS pearl: When a hospitalized patient develops new fever + rash + eosinophilia 3 weeks into an antibiotic or anticonvulsant, stop the culprit immediately, check CBC/LFTs/Cr, and consult dermatology — DRESS has 10% mortality and can flare even after the drug is stopped.

Diagnostic Workup — Initial Labs and Bedside Tests

— CBC with differential — cytopenias (chemo, linezolid, valproate, ticlopidine; eosinophilia in DRESS)

— BMP — AKI (NSAIDs, ACEi/ARB, aminoglycosides, contrast, vancomycin), hyperkalemia (K-sparing diuretics, ACEi, TMP-SMX, heparin), hyponatremia (thiazides, SSRIs, carbamazepine)

— LFTs — hepatocellular (acetaminophen, INH, statins, methotrexate) vs cholestatic (amox-clav, erythromycin, anabolic steroids) pattern

— CK — rhabdomyolysis from statins, especially with CYP3A4 inhibitor or fibrate combo

— Lipase — DRESS, valproate, GLP-1 agonists, azathioprine

— TSH if amiodarone, lithium, or checkpoint inhibitor use

— QTc on antipsychotics, methadone, ondansetron, fluoroquinolones, macrolides, citalopram (>20 mg in elderly is contraindicated), antiarrhythmics

— Bradycardia/AV block: digoxin, beta-blocker/CCB toxicity, donepezil

— Wide QRS: TCA, cocaine, type IA/IC antiarrhythmics → consider sodium bicarbonate

— Digoxin, lithium, phenytoin (correct for albumin), valproate, vancomycin (AUC-based), aminoglycosides, tacrolimus/cyclosporine, theophylline

— Acetaminophen at 4 hours post-ingestion → Rumack-Matthew nomogram

— Salicylate, methanol, ethylene glycol when toxic ingestion suspected

— Urine drug screen for occult ingestion or noncompliance investigation

— Anion and osmolar gaps for toxic alcohols

Baseline ADE-suspicion panel (high yield to order early):

ECG when indicated:

Drug levels — order when level guides management:

Adherence/toxicology adjuncts:

Step 3 management: When you suspect an ADE, (1) hold the suspected drug, (2) check relevant labs/ECG/level, (3) document a reaction in the chart and EHR allergy list with the specific manifestation — vague "allergy" entries cause downstream prescribing errors and deprive patients of effective therapy.

Diagnostic Workup — Causality Assessment and Confirmatory Studies

— Awards points for previous reports, temporal relationship, improvement on dechallenge, recurrence on rechallenge, alternative causes, dose-response, drug levels in toxic range, and objective evidence

— Score ≥9 definite, 5–8 probable, 1–4 possible, ≤0 doubtful

— Useful but rarely tested directly — the concept of dechallenge/rechallenge is high-yield

— Heparin-induced thrombocytopenia (HIT): 4T score first → if intermediate/high, send anti-PF4 ELISA (high sensitivity), confirm with serotonin release assay (high specificity); stop all heparin, including flushes, and start argatroban or fondaparinux

— Drug-induced lupus: anti-histone antibodies (hydralazine, procainamide, isoniazid, minocycline); ANA positive but anti-dsDNA usually negative

— DRESS: RegiSCAR criteria; biopsy supportive; viral reactivation panel (HHV-6) sometimes drawn

— Drug allergy clarification: referral to allergy for penicillin skin testing — >90% of self-reported penicillin allergies are not true allergies; clearing the label expands therapy options and reduces broad-spectrum antibiotic use

— Anaphylaxis: serum tryptase within 1–2 hours of reaction (elevated supports mast cell degranulation)

— Renal ultrasound to rule out obstruction in drug-induced AKI

— CT chest for amiodarone, methotrexate, nitrofurantoin, or checkpoint-inhibitor pneumonitis

— Is there a plausible mechanism and class effect?

— Did symptoms resolve on dechallenge (most important)?

— Are alternative diagnoses excluded?

Establishing drug causation — Naranjo Adverse Drug Reaction Probability Scale:

Specific confirmatory tests:

Imaging when relevant:

Causality vs coincidence — questions to ask:

Key distinction: Type A reactions are predictable, dose-dependent extensions of pharmacology (warfarin bleeding, opioid sedation) — manage with dose reduction. Type B reactions are idiosyncratic, immune-mediated, or genetic (SJS, DRESS, malignant hyperthermia) — require permanent discontinuation and EHR allergy documentation.

Board pearl: Rechallenge is contraindicated for any severe cutaneous adverse reaction (SCAR), anaphylaxis, or organ-specific immune injury — confirmation comes from history and labs, not from "trying again."

Risk Stratification and Prevention Framework

— Prescribing (~50% of preventable ADEs): CPOE with clinical decision support, drug-interaction alerts, weight/renal-based dosing, Beers/STOPP screening

— Transcribing: eliminate handwriting via CPOE; avoid dangerous abbreviations ("U" → units, "QD" → daily, trailing zeros)

— Dispensing: barcoded medications, pharmacist verification, tall-man lettering for look-alike/sound-alike drugs (hydrALAZINE vs hydrOXYzine)

— Administering: "5 rights" (right patient/drug/dose/route/time), barcode scanning at bedside, two-RN check for high-alert drugs (insulin, heparin, chemo, opioids)

— Monitoring: scheduled labs (INR, K+, Cr, drug levels), patient-reported symptom check-ins, structured follow-up

— Polypharmacy: ≥5 chronic meds doubles ADE risk; ≥10 meds quadruples it

— Geriatric high-risk drugs (Beers Criteria): benzodiazepines, first-gen antihistamines, anticholinergics, muscle relaxants, sliding-scale insulin, long-acting sulfonylureas (glyburide), NSAIDs in CKD/CHF

— Renal/hepatic dysfunction: mandatory dose adjustment screen

— Pregnancy: category review and lactation considerations

The Swiss Cheese model of ADE prevention — errors must penetrate multiple layers (prescribing, transcribing, dispensing, administering, monitoring); system-level fixes are more effective than individual blame.

Five stages where ADEs occur — and the prevention strategy at each:

Patient-level risk stratification:

High-alert medications (ISMP list): anticoagulants, opioids, insulin, chemotherapy, neuromuscular blockers, concentrated electrolytes — require independent double-check and dedicated workflows.

Step 3 management: At every visit for a patient on ≥5 meds, perform deprescribing review — for each drug ask: (1) Is there still an indication? (2) Is the benefit > harm? (3) Are there safer alternatives? (4) Can the dose be reduced? This is a high-yield ambulatory Step 3 task.

CCS pearl: Document medication reconciliation at admission, transfer, and discharge — failure to reconcile is the most common root cause of post-discharge ADEs.

Pharmacotherapy — Reversal Agents and Specific Antidotes

— Acetaminophen → N-acetylcysteine (within 8–10 h ideal; effective up to 24 h)

— Opioids → naloxone (titrate to respiratory drive, not full alertness, in chronic users)

— Benzodiazepines → flumazenil (avoid in chronic users or co-ingestion — seizure risk)

— Warfarin → 4-factor PCC (preferred for major bleed) + IV vitamin K; FFP if PCC unavailable

— Dabigatran → idarucizumab

— Apixaban/rivaroxaban → andexanet alfa (or 4F-PCC)

— Heparin → protamine sulfate (partial for LMWH)

— Beta-blocker overdose → glucagon, high-dose insulin/dextrose, IV lipid emulsion

— CCB overdose → calcium, high-dose insulin/dextrose, vasopressors

— Digoxin → digoxin-specific Fab (DigiFab) for life-threatening arrhythmia, K+ >5, level >10, or large ingestion

— TCA → sodium bicarbonate for QRS >100 ms

— Methanol/ethylene glycol → fomepizole + dialysis

— Iron → deferoxamine

— Lead → succimer (children) or EDTA/dimercaprol (severe)

— Organophosphates → atropine + pralidoxime

— Methotrexate → leucovorin; glucarpidase for severe AKI with high MTX

— Sulfonylurea hypoglycemia → dextrose + octreotide (blunts insulin rebound)

— Isoniazid seizures → pyridoxine (B6)

— Cyanide → hydroxocobalamin

— Anaphylaxis: IM epinephrine 0.3–0.5 mg in the anterolateral thigh is first-line — not antihistamines or steroids

— Serotonin syndrome: stop offending agent, benzodiazepines, cyproheptadine for refractory cases; cool

— NMS: stop antipsychotic, supportive care, dantrolene or bromocriptine for severe cases

High-yield antidotes (memorize cold):

Symptomatic management principles:

Board pearl: Activated charcoal is useful only within ~1 hour of ingestion and is contraindicated for caustics, hydrocarbons, lithium, iron, alcohols, and patients with unprotected airways.

Step 3 management: For any suspected significant ingestion, contact Poison Control (1-800-222-1222) early — documented as a quality measure and frequently the right-answer step on CCS cases.

Systems Interventions — Preventing ADEs at the Organizational Level

— Reduces serious medication errors by ~50%

— Embeds dose ranges, renal/hepatic adjustments, allergy alerts, drug-drug interaction warnings, duplicate therapy checks

— Risk: alert fatigue — over 90% of alerts are overridden; tiered alerts (interruptive only for high-severity) improve signal-to-noise

— Required at admission, every level-of-care transfer, and discharge

— Best performed by pharmacist when available — reduces discrepancies by >50%

— Includes OTC, herbals, and PRN; verify with patient, family, pharmacy records

— Reduces wrong-drug and wrong-patient errors during administration

— Effective only if workarounds (e.g., scanning a pre-printed sheet) are eliminated

— Clinical pharmacist on rounds reduces preventable ADEs ~70% in ICU

— Discharge medication counseling and post-discharge phone calls cut 30-day readmissions

— Anticoagulation clinics improve INR time-in-therapeutic-range

— Pre-printed order sets and protocols (DKA, sepsis, VTE prophylaxis)

— Smart pumps with dose-error reduction software

— Single-strength vials; removing concentrated potassium from floors

— "Do not use" abbreviation list (U, IU, QD, QOD, MS, trailing zero, naked decimal)

— Voluntary internal reporting + root cause analysis (RCA) for serious events

— FDA MedWatch for post-marketing surveillance

— Just culture — separates human error (console), at-risk behavior (coach), and reckless behavior (discipline)

CPOE (Computerized Provider Order Entry) with clinical decision support:

Medication reconciliation (Joint Commission National Patient Safety Goal):

Barcode medication administration (BCMA):

Pharmacist-led interventions:

Standardization tactics:

Reporting and learning systems:

Key distinction: A near miss (caught before reaching patient) is reportable and analyzed identically to an adverse event — both reveal latent system flaws. A sentinel event is an unexpected occurrence involving death or severe harm and triggers mandatory RCA.

Board pearl: When a Step 3 question asks how to prevent a recurring error, choose the system-level fix (CPOE rule, protocol, barcode) over "educate the staff" — education alone is the weakest intervention.

Special Populations — Elderly and Renal/Hepatic Impairment

— ↓ lean body mass, ↑ adipose → longer half-life of lipophilic drugs (diazepam, amiodarone)

— ↓ GFR even with "normal" creatinine — use Cockcroft-Gault, not just serum Cr

— ↓ hepatic Phase I (CYP) metabolism; Phase II (conjugation) preserved

— ↑ receptor sensitivity to CNS drugs, anticholinergics, anticoagulants

— Start low, go slow; one new drug at a time when feasible

— Benzodiazepines, Z-drugs: falls, fractures, delirium, MVAs

— First-gen antihistamines (diphenhydramine): anticholinergic delirium

— Anticholinergics: oxybutynin, TCAs — cognitive decline, urinary retention

— Glyburide: prolonged hypoglycemia

— Skeletal muscle relaxants: sedation, falls

— NSAIDs: GI bleed, AKI, HTN, CHF exacerbation

— Antipsychotics in dementia: ↑ mortality (black box)

— PPIs >8 weeks without indication: C. diff, fractures, hypomagnesemia

— Reduce or avoid: gabapentin, pregabalin, metformin (avoid eGFR <30), enoxaparin (avoid eGFR <30 for treatment dosing — use UFH), NOACs (varies), allopurinol, digoxin, atenolol, vancomycin, aminoglycosides, opioids (especially morphine, codeine, meperidine — accumulating metabolites)

— Avoid acetaminophen >2 g/day in cirrhosis

— Avoid NSAIDs (variceal bleed, hepatorenal)

— Reduce benzodiazepines — prefer lorazepam, oxazepam, temazepam (LOT — glucuronidation only)

— Statins generally safe but monitor; avoid in decompensated disease

Geriatric pharmacology principles:

Beers Criteria high-risk in elderly — avoid or use with caution:

STOPP/START criteria: complement Beers — STOPP flags potentially inappropriate prescriptions; START flags omissions of beneficial therapy (e.g., statin in DM with CV risk, anticoagulant in AF).

Renal dose adjustment red flags:

Hepatic impairment adjustments:

Step 3 management: At every elderly visit, conduct a structured deprescribing review using Beers — particularly target benzodiazepines, anticholinergics, sliding-scale insulin, and chronic PPIs; taper rather than abruptly stop sedatives and beta-blockers.

Special Populations — Pregnancy, Lactation, and Pediatrics

— ACEi/ARBs: renal dysgenesis, oligohydramnios (2nd/3rd trimester)

— Warfarin: nasal hypoplasia, stippled epiphyses, CNS abnormalities

— Isotretinoin: craniofacial, cardiac, CNS — iPLEDGE program mandatory

— Valproate: neural tube defects, ↓ IQ — highest teratogenic AED

— Phenytoin/carbamazepine: fetal hydantoin syndrome, NTDs

— Methotrexate, mycophenolate: spontaneous abortion, multiple anomalies

— Lithium: Ebstein's anomaly (small absolute risk)

— Tetracyclines: dental staining, bone growth inhibition (>2nd trimester)

— Aminoglycosides: ototoxicity

— Fluoroquinolones: cartilage concerns

— Statins: generally avoided

— NSAIDs: premature ductus closure after 30 weeks; avoid in 3rd trimester

— SSRIs: paroxetine (cardiac), neonatal adaptation syndrome, persistent pulmonary hypertension

— Acetaminophen, methyldopa/labetalol/nifedipine (HTN), insulin, levothyroxine, heparin/LMWH (do not cross placenta), penicillins/cephalosporins/azithromycin, prenatal vitamins with folate

— Weight-based dosing — mg/kg, not adult fixed doses; double-check decimal placement (10x errors are classic high-harm)

— Aspirin → Reye syndrome in viral illness; avoid <18

— Codeine and tramadol contraindicated <12 due to CYP2D6 ultra-rapid metabolizer risk

— Tetracyclines <8 years (teeth/bone)

— Ceftriaxone in neonates (kernicterus with hyperbilirubinemia; biliary sludge; incompatible with calcium-containing IV fluids)

— Fluoroquinolones generally avoided (cartilage)

Pregnancy — known teratogens (recognize the patterns):

Generally acceptable in pregnancy:

Lactation: most drugs are compatible; major exceptions include amiodarone, chemotherapy, radioactive isotopes, lithium (relative), and recreational drugs. LactMed is the reference standard.

Pediatric ADE considerations:

Board pearl: In a pregnant patient on a known teratogen for a chronic condition (e.g., epilepsy on valproate planning pregnancy), the preconception switch — not first-trimester switch — is the right answer. For unplanned pregnancy already exposed, continue safest effective therapy and refer to MFM; abrupt discontinuation can be more harmful than continued exposure (e.g., uncontrolled seizures).

Complications and Adverse Outcomes of ADEs

— AKI: NSAIDs, ACEi/ARB, contrast, aminoglycosides, vancomycin, amphotericin, tenofovir, cisplatin; AIN from PPIs, beta-lactams, NSAIDs (sterile pyuria, eosinophiluria, WBC casts)

— Hepatotoxicity: acetaminophen (zone 3 necrosis), INH, statins, amox-clav (cholestatic, classic 2–4 weeks post), methotrexate, valproate, amiodarone; checkpoint inhibitor hepatitis

— Cardiotoxicity: anthracycline cardiomyopathy (dose-dependent, monitor LVEF), trastuzumab (reversible), 5-FU/capecitabine vasospasm, QTc prolongation

— Pulmonary: amiodarone fibrosis, methotrexate pneumonitis, nitrofurantoin (acute hypersensitivity and chronic fibrosis), bleomycin fibrosis, ACEi cough/angioedema

— Hematologic: clozapine agranulocytosis (mandatory ANC monitoring via REMS), linezolid thrombocytopenia, HIT, aplastic anemia (chloramphenicol, carbamazepine)

— Endocrine: amiodarone thyroid disease (hyper- or hypo-), checkpoint inhibitor endocrinopathies (hypophysitis, thyroiditis, T1DM, adrenalitis), steroid-induced diabetes and adrenal suppression

— SJS (<10% BSA), SJS/TEN overlap (10–30%), TEN (>30%) — mortality up to 30–50% in TEN; supportive care in burn unit; never rechallenge

— DRESS — multi-organ; eosinophilia; viral reactivation; mortality ~10%

— AGEP — pustular, neutrophilia, beta-lactams; usually benign

— Falls and hip fractures from sedatives, antihypertensives, antipsychotics

— Delirium from anticholinergics, benzodiazepines, opioids in the elderly

— C. difficile from antibiotics + PPIs

— Prescribing cascade: drug A causes side effect → drug B prescribed for the side effect → drug B causes its own ADE (e.g., amlodipine edema → furosemide → hyponatremia/AKI)

Acute organ-specific complications:

Severe cutaneous adverse reactions (SCARs):

Functional and downstream harms:

Key distinction: Drug-induced AIN typically presents 7–10 days after exposure (sooner on rechallenge) with rash, fever, eosinophilia, and AKI — but the classic triad is present in <10%; sterile pyuria with WBC casts is more sensitive. Stop drug; steroids are considered if no improvement.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Airway compromise (angioedema, anaphylaxis, severe sedation)

— Hemodynamic instability requiring vasopressors (beta-blocker/CCB OD, anaphylaxis, sepsis from C. diff)

— Severe acid-base derangement (toxic alcohols, salicylates)

— Refractory arrhythmia or QRS widening (TCA, digoxin, antiarrhythmics)

— Status epilepticus (INH, bupropion, tramadol, withdrawal)

— Hyperthermia >40°C (NMS, serotonin syndrome, malignant hyperthermia, anticholinergic)

— Need for continuous antidote infusion (insulin/dextrose, fomepizole + dialysis, hydroxocobalamin)

— Severe SCAR (TEN) — burn unit or ICU with wound care expertise

— Medical toxicology / Poison Control: any significant ingestion or unfamiliar exposure

— Nephrology: dialysis for toxic alcohols, salicylates >100 mg/dL, lithium >4 or symptomatic >2.5, severe metformin lactic acidosis, refractory hyperkalemia

— Hematology: HIT confirmation and anticoagulation choice, TTP from drugs (quinine, ticlopidine)

— Dermatology: SJS/TEN, DRESS — biopsy and management

— Allergy/Immunology: drug desensitization (penicillin in syphilis pregnancy, aspirin in CAD with intolerance), penicillin skin testing

— Cardiology: persistent QTc >500, drug-induced cardiomyopathy

— Hepatology: ALF — King's College criteria for transplant listing (acetaminophen: pH <7.3 or INR >6.5 + Cr >3.4 + grade III/IV encephalopathy)

— Admit: ongoing organ injury, need for serial labs/levels, antidote requiring infusion, unresolved hemodynamic compromise, suicidality

— Observation: stable ingestion needing serial monitoring (e.g., 4-hour acetaminophen, sustained-release products require longer)

— Discharge: clearly resolved minor reaction, identified culprit removed, reliable follow-up, no high-risk co-morbidities

ICU-level criteria in suspected ADE/toxicity:

Specialty consultation triggers:

Inpatient vs ED observation vs discharge home:

CCS pearl: On a CCS case with suspected significant overdose, the early high-yield orders are: airway assessment, IV access, monitor, fingerstick glucose, ECG, acetaminophen + salicylate levels (every overdose), pregnancy test, contact Poison Control, and consider activated charcoal if <1 hour and airway protected.

Key Differentials — Other Causes Mimicking ADEs

— Pre-renal: dehydration, sepsis, CHF, hepatorenal — check FENa, urine sediment

— Intrinsic: ATN (ischemia or nephrotoxin), AIN (drug or autoimmune), GN

— Post-renal: BPH, stones, retention from anticholinergics (also ADE!)

— Differentiate from contrast nephropathy, rhabdomyolysis, abdominal compartment syndrome

— Drug-induced delirium (anticholinergic, benzo, opioid, steroid)

— Infection (UTI, pneumonia, meningitis, sepsis)

— Metabolic: hyponatremia, hypoglycemia, hypercalcemia, uremia, hepatic encephalopathy, thyroid storm/myxedema

— Neurologic: stroke, NCSE, post-ictal, subdural

— Withdrawal: alcohol, benzodiazepines

— Viral exanthem (especially EBV + amoxicillin "ampicillin rash" — not a true allergy)

— Contact dermatitis, scabies, secondary syphilis, Lyme

— Autoimmune: cutaneous lupus, dermatomyositis

— Drug-induced (chemo, linezolid, valproate, methotrexate, ticlopidine) vs primary marrow failure, B12/folate deficiency, hypersplenism, ITP, TTP, DIC, leukemia

— ADE (ACEi/ARB, spironolactone, TMP-SMX, heparin, beta-blocker, NSAIDs) vs AKI, adrenal insufficiency, tumor lysis, rhabdomyolysis, acidosis, pseudohyperkalemia (hemolysis)

— Drugs vs congenital LQTS, electrolyte derangement (low K, Mg, Ca), MI, ICH, hypothyroidism

— Drug pneumonitis vs infection (PJP, fungal, viral), pulmonary edema, alveolar hemorrhage, progressive cancer

AKI in a hospitalized patient on multiple drugs:

New altered mental status on polypharmacy:

Rash on a new medication:

Cytopenias:

Hyperkalemia:

QT prolongation:

Pulmonary infiltrates on chemotherapy/immunotherapy:

Key distinction: When a patient on immune checkpoint inhibitors develops diarrhea, hepatitis, pneumonitis, or endocrinopathy, treat as immune-related adverse event (irAE) first — hold the drug and give high-dose corticosteroids while infectious workup proceeds. Delaying steroids to "rule out infection completely" worsens outcomes.

Board pearl: Always stop the suspected drug while working up the differential — the diagnostic information from dechallenge is often the most decisive piece of evidence.

Key Differentials — Other-Category Causes and Mimics

— Vasovagal syncope (bradycardia, no urticaria)

— Scombroid poisoning (histamine from spoiled fish — flushing, GI; resolves with antihistamines)

— Carcinoid syndrome (flushing, diarrhea, right heart lesions)

— Systemic mastocytosis (recurrent episodes, elevated baseline tryptase)

— Hereditary angioedema (C1-INH deficiency — bradykinin-mediated; does not respond to epi/steroids/antihistamines; treat with C1-INH concentrate, icatibant, or ecallantide) — distinguish from ACEi angioedema (also bradykinin-mediated, more common in Black patients, can occur years into therapy)

— Anticholinergic toxicity: dry skin, absent bowel sounds (vs diaphoresis and hyperactive bowel sounds in serotonergic)

— Malignant hyperthermia: triggered by volatile anesthetics + succinylcholine

— Sympathomimetic toxicity: cocaine, amphetamines, MDMA

— Sepsis, meningitis, encephalitis, thyroid storm

— Viral (HAV/B/C/E, HSV, EBV, CMV)

— Autoimmune hepatitis (ANA, ASMA, IgG elevation)

— Ischemic hepatitis ("shock liver" — ALT often >1000s, rapid resolution)

— Wilson disease, hemochromatosis, alpha-1 antitrypsin

— Budd-Chiari, biliary obstruction

— Hypothyroidism (check TSH before stopping statin), vitamin D deficiency, polymyalgia rheumatica, inflammatory myopathy, viral myositis

— Immune-mediated necrotizing myopathy (anti-HMGCR antibodies) — rare statin complication that persists after stopping

— Idiopathic SLE (anti-dsDNA, anti-Sm positive; renal/CNS involvement common — rare in DIL)

Mimics of anaphylaxis:

Mimics of serotonin syndrome and NMS:

Mimics of drug-induced hepatitis:

Mimics of statin myopathy:

Mimics of drug-induced lupus:

Key distinction: ACEi angioedema can present months to years after starting the drug, lacks urticaria, and does not respond to epinephrine/antihistamines/steroids the way IgE-mediated anaphylaxis does — secure airway, stop ACEi permanently, consider icatibant or FFP in severe cases, and document the reaction so no future ACEi/ARB is given (ARBs have lower but real cross-reactivity risk).

Secondary Prevention and Long-Term Plan

— Specific drug name (generic and brand)

— Reaction type (rash, anaphylaxis, AKI, GI upset) — not just "allergy"

— Severity and date

— Whether rechallenge is contraindicated, requires desensitization, or is acceptable at a lower dose

— Identify each medication on the list and ask whether it was started to treat a side effect of another drug

— Classic cascades: CCB → edema → diuretic; metoclopramide → parkinsonism → levodopa; donepezil → urinary urgency → oxybutynin (which then worsens cognition)

— Indication, expected benefit, side effect profile, monitoring plan for each new drug

— "Teach-back" technique to confirm understanding

— Written medication list updated at every visit, in the patient's primary language

— MedicAlert bracelet for severe allergies, anticoagulation, insulin

— Identify a single coordinating prescriber (usually PCP) when multiple specialists prescribe

— Use one pharmacy when possible — pharmacist sees the full list and can flag interactions

— Discharge prescriptions: e-prescribe, ensure no duplicate therapy with home meds, eliminate discontinued home meds explicitly

— Highest ADE risk period; >40% of patients have a medication discrepancy at discharge

— Schedule follow-up visit within 7–14 days; phone call within 48–72 hours

— Bridge prescriptions, prior authorizations addressed before discharge

— Confirm patient can afford and access each medication

Document the reaction precisely in the EHR:

Update the problem list and allergy module — vague "PCN allergy" labels lead to broader, costlier, less effective antibiotic use; clarify and de-label when possible via allergy referral and skin testing.

Prescribing cascade reversal:

Patient and caregiver education:

Care coordination:

Vulnerable transitions — the 30-day post-discharge window:

Step 3 management: At every visit, perform a "brown bag" medication review — patient brings all bottles, you reconcile against the EHR, deprescribe inappropriate agents, and ensure indications and durations are current. This is a board-favored ambulatory task.

Follow-Up, Monitoring Parameters, and Counseling

— Warfarin: INR initially every few days, then weekly, then monthly when stable; goal 2–3 (mechanical mitral valve 2.5–3.5)

— DOACs: annual CBC, renal/hepatic function; more frequently if CKD

— Statins: baseline LFTs (no routine recheck unless symptoms); CK only if symptomatic

— Metformin: eGFR annually; B12 every 1–2 years on long-term use

— ACEi/ARB: BMP at 1–2 weeks after initiation and dose changes — accept up to 30% Cr rise

— Spironolactone: K+ and Cr at 1 week, 1 month, then periodically

— Diuretics: BMP within 1–2 weeks; periodic

— Lithium: trough level every 6–12 months when stable; TSH and Cr every 6–12 months; trough goal 0.6–1.0 mEq/L (acute 0.8–1.2)

— Amiodarone: baseline + every 6 months — TSH, LFTs; annual CXR; annual ophthalmologic; PFTs if symptoms

— Methotrexate: CBC, LFTs, Cr every 1–3 months; folate supplementation

— TNF inhibitors: annual TB screening; hepatitis B before start

— Clozapine: ANC weekly × 6 mo, then biweekly × 6 mo, then monthly (REMS)

— Isotretinoin (iPLEDGE): monthly pregnancy tests, two forms of contraception, monthly lipids/LFTs

— Antipsychotics: weight, BP, lipids, glucose, AIMS for tardive dyskinesia

— Opioids: PDMP check every prescription, urine drug screen periodically, naloxone co-prescription for high-dose or co-prescribed benzo

— Why this drug, expected benefit, when to expect it

— Common side effects vs danger signs

— Interactions including OTC and grapefruit

— What to do if a dose is missed

— When and how monitoring labs will occur

Drug-specific monitoring schedules (high-yield):

Patient counseling essentials at every initiation:

Board pearl: When given a stem with a patient on a new chronic medication, the first follow-up window is typically 1–2 weeks for labs/effect and 4–6 weeks for clinical response assessment — choose the answer that includes both monitoring labs and clinical reassessment, not just "return in 3 months."

Ethical, Legal, and Patient Safety Considerations

— Ethical and (in many states) legal duty to disclose harm to the patient promptly

— Use clear, non-defensive language: what happened, what is being done, what will change to prevent recurrence

— Apology laws in most US states protect expressions of sympathy from being admissible — disclosure is associated with lower litigation rates, not higher

— Document disclosure conversation in the chart

— Distinguish human error (slip, console and learn), at-risk behavior (drift from policy, coach), and reckless behavior (conscious disregard, discipline)

— Punishing honest reporting destroys the safety-event pipeline that drives system improvement

— Serious ADEs and product problems → FDA MedWatch (voluntary for clinicians, mandatory for manufacturers)

— Vaccine adverse events → VAERS (mandatory for clinicians)

— Sentinel events → internal RCA; some states require external reporting

— Suspected child/elder abuse precipitated by medication mismanagement → mandatory state reporting

— Off-label prescribing is legal but the patient should be informed

— Black-box warnings (e.g., antidepressants and suicidality in adolescents) should be discussed and documented

— Capacity assessment for a patient refusing a beneficial medication or insisting on a potentially harmful one

— Discharge medication reconciliation is a Joint Commission NPSG and a CMS quality measure

— Failure to reconcile is the most common root cause of post-discharge ADEs

— High-risk drugs requiring explicit discharge planning: anticoagulants, insulin, opioids, immunosuppressants, antiepileptics

— Patients on warfarin discharged without follow-up INR within 7 days have markedly elevated bleeding and thrombosis rates

Disclosure of medical errors:

Just culture in error response:

Mandatory reporting:

Informed consent edge cases:

Transition-of-care safety (a Step 3 favorite):

Conflicts of interest: disclose pharmaceutical relationships; Open Payments (Sunshine Act) database publicly reports industry payments to physicians.

Step 3 management: When a Step 3 vignette describes a medication error that reached the patient (e.g., wrong-dose insulin causing hypoglycemia), the correct sequence is: (1) stabilize the patient, (2) disclose to patient/family promptly and honestly, (3) report through the institutional event-reporting system, (4) participate in RCA, (5) implement a system-level fix — not blame the individual nurse or pharmacist.

High-Yield Associations and Rapid-Fire Clinical Facts

— ACEi → cough, angioedema, hyperkalemia

— Amiodarone → thyroid, pulmonary, hepatic, corneal deposits, blue skin

— Amphotericin → hypoK, hypoMg, AKI, infusion reactions

— Bleomycin → pulmonary fibrosis

— Carbamazepine → SIADH, agranulocytosis, SJS (HLA-B*1502 in Asians)

— Cisplatin → ototoxicity, nephrotoxicity, peripheral neuropathy

— Clozapine → agranulocytosis, myocarditis, seizures, metabolic

— Cyclophosphamide → hemorrhagic cystitis (mesna prevents), bladder cancer, SIADH

— Digoxin → yellow vision, AV block, atrial tachycardia with block

— Doxorubicin → cardiomyopathy

— Fluoroquinolones → tendon rupture, QT, aortic dissection, peripheral neuropathy, dysglycemia

— Furosemide → ototoxicity, hypoK, hypoMg, hyperuricemia

— Heparin → HIT, osteoporosis

— Hydralazine → drug-induced lupus

— Isoniazid → hepatitis (especially with alcohol), peripheral neuropathy (give B6), drug-induced lupus

— Lithium → tremor, nephrogenic DI, hypothyroid, Ebstein's

— Methotrexate → marrow, hepatic, pulmonary, mucositis (folate rescue)

— Metronidazole → disulfiram reaction, metallic taste, peripheral neuropathy

— Nitrofurantoin → pulmonary fibrosis, hemolysis in G6PD

— Phenytoin → gingival hyperplasia, hirsutism, megaloblastic anemia, cerebellar, SJS (HLA-B*1502)

— Procainamide → drug-induced lupus

— Sulfonamides → SJS, hemolysis in G6PD, AKI, hyperkalemia (TMP)

— Tamoxifen → endometrial cancer, VTE, hot flashes

— Trastuzumab → reversible cardiomyopathy

— Vancomycin → red-man syndrome (infusion rate — not allergy), AKI, ototoxicity

Drug → classic side effect (rapid recall):

CYP3A4 inhibitors (raise levels of statins, CCBs, immunosuppressants, warfarin): "GPACMAN" — Grapefruit, Protease inhibitors, Azoles, Cimetidine, Macrolides (not azithro), Amiodarone, Non-DHP CCBs.

CYP inducers (drop levels): "CRAP GPS" — Carbamazepine, Rifampin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbital, St. John's wort.

Board pearl: A patient on simvastatin who develops myalgia/CK rise shortly after starting clarithromycin or itraconazole = classic CYP3A4 interaction. Switch to azithromycin or hold the statin temporarily.

Board Question Stem Patterns

— Elderly woman on amlodipine presents with bilateral ankle edema → next step is reduce or stop amlodipine, NOT add furosemide (prescribing cascade trap)

— Patient on warfarin develops elevated INR after starting TMP-SMX (or amiodarone, ciprofloxacin, metronidazole, fluconazole) → hold warfarin, reverse if bleeding

— Elderly woman with eGFR 25 on metformin develops lactic acidosis → metformin contraindication at eGFR <30

— Black patient on lisinopril develops tongue swelling 6 months in → ACEi angioedema; switch to ARB cautiously or another class; document permanently

— Elderly patient on diphenhydramine + zolpidem + oxybutynin has a fall and confusion → deprescribe; Beers Criteria violations

— Patient receives 10× insulin dose due to look-alike vials → correct answer is system-level fix (tall-man lettering, barcode scanning, separated storage), not "educate nursing staff"

— Patient harmed by medication error; family asks what happened → disclose honestly and promptly, document, file incident report, RCA

— Patient discharged on new warfarin without follow-up → schedule INR in 3–5 days, ensure prescription filled, teach-back diet/interactions, anticoagulation clinic referral

— Woman with epilepsy on valproate planning pregnancy → switch to lamotrigine preconception and add folate

— Agitated patient with clonus, hyperreflexia, diaphoresis after tramadol added to SSRI → serotonin syndrome; stop offending agents, benzos, cyproheptadine if refractory

— Melanoma patient on pembrolizumab develops diarrhea and abdominal pain → irAE colitis; hold drug, start high-dose steroids while ruling out infection

Pattern 1 — The new symptom in a chronic-med patient:

Pattern 2 — The drug-drug interaction:

Pattern 3 — The dose-adjustment miss:

Pattern 4 — The classic class effect:

Pattern 5 — The polypharmacy fall:

Pattern 6 — The system error:

Pattern 7 — The disclosure question:

Pattern 8 — The transition of care:

Pattern 9 — The teratogen swap:

Pattern 10 — The toxidrome:

Pattern 11 — The immune-related AE:

Key distinction: When a stem describes a near-miss caught by a pharmacist, the correct answer emphasizes strengthening the system that caught it (reporting, RCA, process refinement) — not minimizing because no harm occurred. Near misses are gold-standard data for prevention.

One-Line Recap

Adverse drug events are common, often preventable, and best identified by a low-threshold "could this symptom be the drug?" reflex combined with structured medication reconciliation, deprescribing, and system-level safeguards — when they occur, stop the culprit, document precisely, treat with the right antidote, disclose honestly, and fix the system that allowed the error.

Identification: Suspect ADE for any new symptom in a polypharmacy patient — especially within the 30-day post-discharge window or shortly after a new drug, dose change, or interacting drug; dechallenge is the most powerful diagnostic test.

Prevention: Build defenses at every stage — CPOE with decision support, barcode administration, pharmacist-led reconciliation, Beers/STOPP screening, brown-bag reviews, and explicit transitions-of-care planning — system fixes beat education every time.

High-risk drugs to memorize: anticoagulants, insulin and oral hypoglycemics, opioids, antibiotics, antiplatelets, digoxin, and chemotherapy/immunotherapy — these account for the majority of preventable serious ADEs and demand dedicated monitoring.

Response when an ADE occurs: Stabilize → stop the drug → give the specific antidote (NAC, naloxone, vitamin K/PCC, idarucizumab, glucagon, fomepizole, leucovorin, atropine + 2-PAM, hydroxocobalamin, DigiFab) → disclose to patient and family honestly → report through MedWatch/VAERS and institutional channels → conduct root cause analysis → close the latent system gap.

Step 3 management: On every ambulatory and discharge encounter, perform medication reconciliation, deprescribe inappropriate agents (especially in the elderly), update EHR allergies with specific reactions to prevent both undertreatment from spurious labels and rechallenge of true severe reactors, ensure a single coordinating prescriber and a single pharmacy when feasible, and schedule the right monitoring labs and follow-up cadence for each high-risk drug initiated.

Board pearl: When in doubt on a Step 3 stem with a polypharmacy patient and a new symptom — the drug did it, the system enabled it, and the correct answer prioritizes both stopping the offender and fixing the process.